Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Autor: Luen, SJ, Viale, G, Nik-Zainal, S, Savas, P, Kammler, R, Dell'Orto, P, Biasi, O, Degasperi, A, Brown, LC, Láng, I, MacGrogan, G, Tondini, C, Bellet, M, Villa, F, Bernardo, A, Ciruelos, E, Karlsson, P, Neven, P, Climent, M, Müller, B, Jochum, W, Bonnefoi, H, Martino, S, Davidson, NE, Geyer, C, Chia, SK, Ingle, JN, Coleman, R, Solbach, C, Thürlimann, B, Colleoni, M, Coates, AS, Goldhirsch, A, Fleming, GF, Francis, PA, Speed, TP, Regan, MM, Loi, S

Publikováno v: Annals of Oncology. 34:397-409

BACKGROUND: Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+HER2-) early breast cancer (EBC) have higher rates of recurrence and death for reasons that remain largely unex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53a0d3159f258b375d200a64e6a4c921
https://doi.org/10.1016/j.annonc.2023.01.009

Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.

Autor: Mamounas EP; Department of Surgical Oncology, Orlando Health Cancer Institute, Orlando, FL, USA., Bandos H; NRG Oncology SDMC, and the Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA., Rastogi P; University of Pittsburgh Medical Center Hillman Cancer Center, Department of Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Oncology, University of Pittsburgh Magee-Womens Hospital, Pittsburgh, PA, USA., Lembersky BC; University of Pittsburgh Medical Center Hillman Cancer Center, Department of Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Jeong JH; NRG Oncology SDMC, and the Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA., Geyer CE Jr; University of Pittsburgh Medical Center Hillman Cancer Center, Department of Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Fehrenbacher L; Department of Medical Oncology, Kaiser Permanente Oncology Clinical Trials Northern California, Novato, CA, USA., Chia SK; Department of Medical Oncology, British Columbia Cancer Agency (BCCA), Vancouver, British Columbia, Canada., Brufsky AM; Department of Oncology, University of Pittsburgh Magee-Womens Hospital, Pittsburgh, PA, USA., Walshe JM; Department of Oncology, Cancer Trials Ireland (formerly known as Irish Clinical Oncology Research Group-ICORG), Dublin, Ireland., Soori GS; Department of Oncology, Florida Cancer Specialists, Fort Myers, FL, USA., Dakhil SR; Department of Oncology, Community Clinical Oncology Program, Wichita via Christi Regional Medical Center, Wichita, KS, USA., Wade JL 3rd; Department of Oncology, Decatur Memorial Hospital, Cancer Care Specialists of Illinois, Heartland National Cancer Institute Community Oncology Research Program, Decatur, IL, USA., McCarron EC; Department of Surgical Oncology, MedStar Franklin Square Medical Center at Weinberg Cancer Institute, Baltimore, MD, USA., Swain SM; Department of Surgical Oncology, Georgetown Lombardi Comprehensive Cancer Center, MedStar Health, Washington, DC, USA., Wolmark N; NRG Oncology SDMC, and the Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.

Publikováno v: Journal of the National Cancer Institute [J Natl Cancer Inst] 2023 Nov 08; Vol. 115 (11), pp. 1302-1309.

Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study.

Autor: LeVasseur N; Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada., Sun J; Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada., Fenton D; Vancouver Island Centre, British Columbia, V8R 1J8, Canada., Baxter S; Sindi Ahluwalia Hawkins Centre for the Southern Interior, Kelowna, British Columbia, V1Y 5L3, Canada., Chan A; Fraser Valley Centre, Surrey, British Columbia, V3V 1Z2, Canada., Roberts S; Center for the North, Prince George, British Columbia, V2M 7E9, Canada., Feng X; Vancouver Island Centre, British Columbia, V8R 1J8, Canada., Lohrisch C; Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada., Gelmon K; Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada., Shenkier T; Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada., Chia SK; Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada. Electronic address: schia@bccancer.bc.ca.

Publikováno v: Clinical breast cancer [Clin Breast Cancer] 2022 Jan; Vol. 22 (1), pp. e74-e79. Date of Electronic Publication: 2021 Sep 17.

PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study.

Autor: Ballé, Judith Katharina¹ (AUTHOR), Vetter, Martina² (AUTHOR), Kenea, Tariku Wakuma³ (AUTHOR), Eber-Schulz, Pia¹ (AUTHOR), Reibold, Christian¹ (AUTHOR), Ziegenhorn, Hannes-Viktor^1,4 (AUTHOR), Stückrath, Kathrin² (AUTHOR), Wickenhauser, Claudia⁵ (AUTHOR), Addissie, Adamu^1,6 (AUTHOR), Santos, Pablo¹ (AUTHOR), Kantelhardt, Eva Johanna^1,2 (AUTHOR), Getachew, Sefonias^1,6 (AUTHOR), Bauer, Marcus^1,5 (AUTHOR) marcus.bauer@uk-halle.de

Publikováno v: BMC Cancer. 10/9/2024, Vol. 24 Issue 1, p1-11. 11p.

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics.

Autor: Zhang, Xudong¹ (AUTHOR), Kong, Hanqing² (AUTHOR), Liu, Xiaoxue² (AUTHOR), Li, Qingxiang² (AUTHOR), Fang, Xinran² (AUTHOR), Wang, Junjia² (AUTHOR), Qin, Zihao² (AUTHOR), Hu, Nana² (AUTHOR), Tian, Jiawei^2,3 (AUTHOR) jwtian2004@163.com, Cui, Hao^2,3 (AUTHOR) cuihao@hrbmu.edu.cn, Zhang, Lei^1,3 (AUTHOR) zhanglei6@hrbmu.edu.cn

Publikováno v: Cancer Medicine. Sep2024, Vol. 13 Issue 17, p1-14. 14p.